Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to 0.64.

  • Ligand Pharmaceuticals' Equity Ratio fell 2696.3% to 0.64 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.64, marking a year-over-year decrease of 2696.3%. This contributed to the annual value of 0.88 for FY2024, which is 96.45% down from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Equity Ratio of 0.64 as of Q3 2025, which was down 2696.3% from 0.87 recorded in Q2 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Equity Ratio peaked at 0.89 during Q2 2024, and registered a low of 0.58 during Q1 2021.
  • Moreover, its 5-year median value for Equity Ratio was 0.8 (2023), whereas its average is 0.78.
  • In the last 5 years, Ligand Pharmaceuticals' Equity Ratio skyrocketed by 2462.59% in 2022 and then tumbled by 2696.3% in 2025.
  • Ligand Pharmaceuticals' Equity Ratio (Quarter) stood at 0.63 in 2021, then rose by 23.79% to 0.78 in 2022, then rose by 13.65% to 0.89 in 2023, then decreased by 0.96% to 0.88 in 2024, then fell by 27.03% to 0.64 in 2025.
  • Its Equity Ratio was 0.64 in Q3 2025, compared to 0.87 in Q2 2025 and 0.88 in Q1 2025.